V3: HIV's switch-hitter.
暂无分享,去创建一个
Oliver Hartley | Q. Sattentau | John P. Moore | P. Klasse | O. Hartley | John P Moore | Per Johan Klasse | Quentin J Sattentau
[1] M. Dierich,et al. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. , 1999, AIDS research and human retroviruses.
[2] J. Skehel,et al. Structural studies on viral escape from antibody neutralization. , 2001, Current topics in microbiology and immunology.
[3] G. Simmons,et al. Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo , 1999, Journal of Virology.
[4] J. Moore,et al. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. , 1992, AIDS research and human retroviruses.
[5] John P. Moore,et al. Inhibiting sexual transmission of HIV-1 infection , 2003, Nature Reviews Microbiology.
[6] Yiming Shao,et al. Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.
[7] J. Moore,et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.
[8] M. Reitz,et al. Human Immunodeficiency Virus Type 1 IIIB Selected for Replication In Vivo Exhibits Increased Envelope Glycoproteins in Virions without Alteration in Coreceptor Usage: Separation of In Vivo Replication from Macrophage Tropism , 2001, Journal of Virology.
[9] P. Roller,et al. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. , 1997, Biochemistry.
[10] S. Zolla-Pazner,et al. Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1 , 1998, Journal of Virology.
[11] T. F. Rinke de Wit,et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.
[12] Menico Rizzi,et al. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES , 2001, Nature Structural Biology.
[13] Christoph Grundner,et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. , 2003, Virology.
[14] Amanda M. Brown,et al. Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation , 1999, Journal of Virology.
[15] S. Oka,et al. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus , 1994, Journal of virology.
[16] Michal Sharon,et al. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. , 2003, Structure.
[17] W. O'brien. Viral determinants of cellular tropism. , 1992, Pathobiology (Basel).
[18] B. Cullen,et al. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. , 1992, Science.
[19] A. Trkola,et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] F. Gao,et al. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa , 1992, Nature.
[21] R. Desrosiers,et al. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. , 1994, Current topics in microbiology and immunology.
[22] R. Desrosiers. Prospects for an AIDS vaccine , 2004, Nature Medicine.
[23] Lynn Morris,et al. The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.
[24] H. Schuitemaker,et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.
[25] Robyn L Stanfield,et al. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.
[26] L. Arthur,et al. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. , 1992, Science.
[27] A. Yonezawa,et al. Replacement of the V3 Region of gp120 with SDF-1 Preserves the Infectivity of T-Cell Line-Tropic Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.
[28] J. Sodroski,et al. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.
[29] C. Broder,et al. UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .
[30] J. Moore,et al. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 , 1996, Journal of virology.
[31] M. Bendinelli,et al. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system , 1994, Journal of virology.
[32] R. Desrosiers,et al. Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry. , 1993, Virology.
[33] R. Doms,et al. Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. , 2003, Virology.
[34] Reed J. Harris,et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.
[35] C. Cheng‐Mayer,et al. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] Susan Zolla-Pazner,et al. A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response , 2002, Journal of Virology.
[37] Q. Sattentau,et al. Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.
[38] J. Fetrow. Omega loops; nonregular secondary structures significant in protein function and stability , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] Robert Blumenthal,et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[40] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[41] B. Chesebro,et al. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[42] J. Goudsmit,et al. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies , 1993, Journal of virology.
[43] J. Sodroski,et al. CD4-independent binding of SIV gp120 to rhesus CCR5. , 1997, Science.
[44] K. Boulez,et al. The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV‐1 shows pronounced helical character in solution , 1995, FEBS letters.
[45] J. Albert,et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.
[46] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[47] Anne Imberty,et al. Characterization of the Stromal Cell-derived Factor-1α-Heparin Complex* , 2001, The Journal of Biological Chemistry.
[48] B. Cullen,et al. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[49] D. Burton,et al. The antiviral activity of antibodies in vitro and in vivo , 2001, Advances in Immunology.
[50] J. Moore,et al. The role of the V3 loop of gp120 in HIV infection. , 1991, AIDS.
[51] Q. Sattentau,et al. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. , 2002, The Journal of general virology.
[52] J. Manola,et al. Membrane-Fusing Capacity of the Human Immunodeficiency Virus Envelope Proteins Determines the Efficiency of CD4+ T-Cell Depletion in Macaques Infected by a Simian-Human Immunodeficiency Virus , 2001, Journal of Virology.
[53] Deborah Fass,et al. Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.
[54] Stephen C. Blacklow,et al. A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.
[55] John P. Moore,et al. New targets for inhibitors of HIV-1 replication , 2000, Nature Reviews Molecular Cell Biology.
[56] M. Delepierre,et al. Stromal Cell-derived Factor-1α Associates with Heparan Sulfates through the First β-Strand of the Chemokine* , 1999, The Journal of Biological Chemistry.
[57] P. Garnier,et al. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. , 2001, Biochemistry.
[58] R. Gallo,et al. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees , 1990, Journal of virology.
[59] I. Wilson,et al. Crystal structure of the principal neutralization site of HIV-1. , 1994, Science.
[60] V. Maino,et al. Insufficient Production and Tissue Delivery of CD4+Memory T Cells in Rapidly Progressive Simian Immunodeficiency Virus Infection , 2004, The Journal of experimental medicine.
[61] Joseph Sodroski,et al. Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.
[62] Jaap Goudsmit,et al. N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.
[63] L. Pearl,et al. Characterization of HIV‐1 neutralization escape mutants , 1989, AIDS.
[64] J. Mascola,et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.
[65] L. M. Smith,et al. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. , 1993, Virology.
[66] A. Garzino-Demo,et al. The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.
[67] S. Nisole,et al. Spontaneous Mutations in the env Gene of the Human Immunodeficiency Virus Type 1 NDK Isolate Are Associated with a CD4-Independent Entry Phenotype , 1998, Journal of Virology.
[68] R. Doms,et al. HIV-1 entry and its inhibition. , 2003, Current topics in microbiology and immunology.
[69] J. Binley,et al. Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits , 2000, Journal of Virology.
[70] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[71] Joseph Sodroski,et al. Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants , 2001, Journal of Virology.
[72] W. Paxton,et al. Intrapatient Alterations in the Human Immunodeficiency Virus Type 1 gp120 V1V2 and V3 Regions Differentially Modulate Coreceptor Usage, Virus Inhibition by CC/CXC Chemokines, Soluble CD4, and the b12 and 2G12 Monoclonal Antibodies , 2004, Journal of Virology.
[73] J. Levy,et al. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles , 1990, Journal of virology.
[74] I. Wilson,et al. Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. , 2003, Virology.
[75] A. Profy,et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.
[76] H. Dyson,et al. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. , 1991, Biochemistry.
[77] J. Sodroski,et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.
[78] M. Reitz,et al. Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions , 1995, Journal of virology.
[79] L. Stamatatos,et al. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. , 2000, AIDS research and human retroviruses.
[80] Robyn L Stanfield,et al. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. , 2004, Structure.
[81] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[82] J. Mascola,et al. The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.
[83] P. Sharp,et al. Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2). , 2004, AIDS research and human retroviruses.
[84] R. Doms,et al. Modulation of Env Content in Virions of Simian Immunodeficiency Virus: Correlation with Cell Surface Expression and Virion Infectivity , 2004, Journal of Virology.
[85] G. Myers,et al. Solution structure of the V3 loop of a Thailand HIV isolate. , 1993, Journal of biomolecular structure & dynamics.
[86] B. Hahn,et al. Genetically Divergent Strains of Human Immunodeficiency Virus Type 2 Use Multiple Coreceptors for Viral Entry , 1998, Journal of Virology.
[87] T L Hoffman,et al. HIV-1 envelope determinants for cell tropism and chemokine receptor use. , 1999, Molecular membrane biology.
[88] D. Burton,et al. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? , 2000, Nature Medicine.
[89] R. Compans,et al. Effect of the Cytoplasmic Domain of the Simian Immunodeficiency Virus Envelope Protein on Incorporation of Heterologous Envelope Proteins and Sensitivity to Neutralization , 2000, Journal of Virology.
[90] S. A. Gallo,et al. The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.
[91] M. Luscher,et al. Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses. , 2003, AIDS research and human retroviruses.
[92] J. Sodroski,et al. Adaptation of a CCR5-Using, Primary Human Immunodeficiency Virus Type 1 Isolate for CD4-Independent Replication , 1999, Journal of Virology.
[93] J. Margolick,et al. Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.
[94] B. Larder. Mechanisms of HIV-1 drug resistance. , 2001, AIDS.
[95] Kenneth A. Taylor,et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[96] E. Clercq. The Emerging Role of Fusion Inhibitors in HIV Infection , 1999 .
[97] T L Hoffman,et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[98] R. Doms,et al. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[99] C. Barbas,et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.
[100] NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120. , 1997, Journal of biochemical and biophysical methods.
[101] J. Carr,et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. , 2001, AIDS research and human retroviruses.
[102] M. Akutsu,et al. Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene , 1991, Journal of virology.
[103] H. Schuitemaker,et al. Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker , 2004, Journal of Virology.
[104] I. Wilson,et al. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. , 1999, Structure.
[105] W. Blattner,et al. Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course , 2001, Journal of Virology.
[106] C. Weiss. HIV-1 gp41: mediator of fusion and target for inhibition. , 2003, AIDS reviews.
[107] David Yang,et al. The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors , 2000, Journal of Virology.
[108] M. Feinberg,et al. Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.
[109] D. Birx,et al. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. , 1995, AIDS research and human retroviruses.
[110] P. Sharp,et al. AIDS as a zoonosis: scientific and public health implications. , 2000, Science.
[111] R L Stanfield,et al. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[112] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[113] J. Sodroski,et al. CD4-Induced T-20 Binding to Human Immunodeficiency Virus Type 1 gp120 Blocks Interaction with the CXCR4 Coreceptor , 2004, Journal of Virology.
[114] A. Trkola,et al. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines , 1998, Journal of Virology.
[115] J. Sodroski,et al. Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[116] J. Sodroski,et al. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses , 1996, Journal of virology.
[117] J. Murray,et al. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. , 2000, Journal of molecular biology.
[118] John P. Moore,et al. Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.
[119] S. Barnett,et al. Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa. , 2001, AIDS research and human retroviruses.
[120] P. Jagodziński,et al. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes. , 1996, Virology.
[121] R. Doms,et al. Amino Acid 324 in the Simian Immunodeficiency Virus SIVmac V3 Loop Can Confer CD4 Independence and Modulate the Interaction with CCR5 and Alternative Coreceptors , 2004, Journal of Virology.
[122] R. F. Cook,et al. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein , 1995, Journal of virology.
[123] Bette T. Korber,et al. Immune control of HIV: the obstacles of HLA and viral diversity , 2001, Nature Immunology.
[124] D R Burton,et al. gp120: Biologic aspects of structural features. , 2001, Annual review of immunology.
[125] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[126] J. Sodroski,et al. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus , 1992, Journal of virology.
[127] J. Moore,et al. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment , 1995, Journal of virology.
[128] L. Cavacini,et al. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions , 2002, AIDS.
[129] M. Bergeron,et al. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. , 2000, Virology.
[130] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[131] C. Griesinger,et al. Secondary structural elements as a basis for antibody recognition in the immunodominant region of human immunodeficiency viruses 1 and 2. , 1996, European journal of biochemistry.
[132] R. Doms,et al. Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains , 1999, Journal of Virology.
[133] J. Kappes,et al. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.
[134] Noah G. Hoffman,et al. Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.
[135] C. Kuiken,et al. Structure and Function of CC-Chemokine Receptor 5 Homologues Derived from Representative Primate Species and Subspecies of the Taxonomic Suborders Prosimii and Anthropoidea , 2003, Journal of Virology.
[136] Q. Sattentau,et al. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.
[137] N. Skelton,et al. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. , 1997, Biochemistry.
[138] Y. Soda,et al. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. , 1999, Virology.
[139] E. Bradbury,et al. Structure and Polymorphism of HIV-1 Third Variable Loops (*) , 1996, The Journal of Biological Chemistry.
[140] M. Reitz,et al. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization , 1994, Journal of virology.
[141] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[142] Á. McKnight,et al. Cell surface receptors, virus entry and tropism of primate lentiviruses. , 2002, The Journal of general virology.
[143] N. Heveker,et al. Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses , 1999, Journal of Virology.
[144] E. Bradbury,et al. Local and Global Structural Properties of the HIV-MN V3 Loop (*) , 1995, The Journal of Biological Chemistry.
[145] Emmanuel G. Cormier,et al. The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor , 2002, Journal of Virology.
[146] B. Sykes,et al. Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.
[147] B. Sykes,et al. Structure‐activity relationships of chemokines , 1995, Journal of leukocyte biology.
[148] O. Yoshie,et al. T-Tropic Human Immunodeficiency Virus Type 1 (HIV-1)-Derived V3 Loop Peptides Directly Bind to CXCR-4 and Inhibit T-Tropic HIV-1 Infection , 1998, Journal of Virology.
[149] J. Sodroski,et al. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. , 2000, AIDS research and human retroviruses.
[150] R. Cooke,et al. Identification of a glycosaminoglycan binding surface on human interleukin-8. , 1998, Biochemistry.
[151] D. Kabat,et al. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.
[152] M. Reitz,et al. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.
[153] H. Schuitemaker,et al. Phenotypic and Genotypic Comparisons of CCR5- and CXCR4-Tropic Human Immunodeficiency Virus Type 1 Biological Clones Isolated from Subtype C-Infected Individuals , 2004, Journal of Virology.
[154] R. Doms,et al. CD4 Independence of Simian Immunodeficiency Virus Envs Is Associated with Macrophage Tropism, Neutralization Sensitivity, and Attenuated Pathogenicity , 2002, Journal of Virology.
[155] J. Sodroski,et al. Identification of Conserved and Variable Structures in the Human Immunodeficiency Virus gp120 Glycoprotein of Importance for CXCR4 Binding , 2002, Journal of Virology.
[156] D. Bolognesi. Prospects for prevention of and early intervention against HIV. , 1989, JAMA.
[157] R. Doms,et al. Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins , 2003, Journal of Virology.
[158] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[159] Á. McKnight,et al. Immune escape and tropism of HIV. , 1995, Trends in microbiology.
[160] Susan Zolla-Pazner,et al. Identifying epitopes of HIV-1 that induce protective antibodies , 2004, Nature Reviews Immunology.
[161] G K Lewis,et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.
[162] Rami Kantor,et al. High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.
[163] Jianping Ding,et al. Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. , 2002, Structure.
[164] R. Doms,et al. Unique Pattern of Convergent Envelope Evolution in Simian Immunodeficiency Virus-Infected Rapid Progressor Macaques: Association with CD4-Independent Usage of CCR5 , 2003, Journal of Virology.
[165] R. Doms,et al. Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. , 2003, Virology.
[166] P. Lusso. Picking the lock with a hairpin. Did HIV-1 learn the art from chemokines? , 2003, Structure.
[167] V. Hascall,et al. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. , 1993, AIDS research and human retroviruses.
[168] E Bailes,et al. The origins of acquired immune deficiency syndrome viruses: where and when? , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[169] D. Douek. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. , 2003, AIDS reviews.
[170] J. Bhattacharya,et al. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. , 2003, AIDS.
[171] R. Doms,et al. Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein , 2001, Journal of Virology.
[172] John P. Moore,et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.
[173] A. Cunningham,et al. The role of dendritic cell C‐type lectin receptors in HIV pathogenesis , 2003, Journal of leukocyte biology.
[174] S. Dasgupta,et al. The nature of the turn in omega loops of proteins , 2003, Proteins.
[175] Q. Sattentau,et al. Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans , 1998, Journal of Virology.
[176] J. Sodroski,et al. Probability Analysis of Variational Crystallization and Its Application to gp120, The Exterior Envelope Glycoprotein of Type 1 Human Immunodeficiency Virus (HIV-1)* , 1999, The Journal of Biological Chemistry.
[177] E. De Clercq,et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.
[178] P. Bieniasz,et al. Envelope-Dependent, Cyclophilin-Independent Effects of Glycosaminoglycans on Human Immunodeficiency Virus Type 1 Attachment and Infection , 2002, Journal of Virology.
[179] J. Moore,et al. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures , 1994, Journal of virology.
[180] John P. Moore,et al. Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate , 2002, Journal of Virology.
[181] D R Burton,et al. A model for neutralization of viruses based on antibody coating of the virion surface. , 2001, Current topics in microbiology and immunology.
[182] J. Sodroski,et al. Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus , 2000, Journal of Virology.
[183] R. Doms,et al. DC-SIGN and DC-SIGNR: helping hands for HIV. , 2001, Trends in immunology.
[184] J. Goudsmit,et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. , 1994, Virology.
[185] H. Dyson,et al. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. , 1997, Journal of molecular biology.
[186] Jon Cohen. AIDS Vaccine Trial Produces Disappointment and Confusion , 2003, Science.
[187] M. Reitz,et al. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. , 1993, The Journal of biological chemistry.
[188] B. Haynes,et al. NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. , 1994, Biochemistry.
[189] J. Sodroski,et al. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. , 2004, Virology.
[190] John P. Moore,et al. Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development , 2001, Journal of Virology.
[191] J. Sodroski,et al. Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120 , 2000, Journal of Virology.
[192] C. Debouck,et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[193] P. Marx,et al. The function of simian chemokine receptors in the replication of SIV. , 1998, Seminars in immunology.
[194] R. Doms,et al. CD4-Independent Use of Rhesus CCR5 by Human Immunodeficiency Virus Type 2 Implicates an Electrostatic Interaction between the CCR5 N Terminus and the gp120 C4 Domain , 2001, Journal of Virology.
[195] Michael Greenberg,et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.
[196] P. Berman,et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.
[197] J. Sodroski,et al. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change , 1994, Journal of virology.
[198] M. Reitz,et al. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. , 1993, Virology.
[199] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[200] R. Weiss,et al. CD4-dependent and CD4-independent HIV-2: consequences for neutralization , 2003, AIDS.
[201] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[202] R. Weiss,et al. Change in tropism upon immune escape by human immunodeficiency virus , 1995, Journal of virology.
[203] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[204] D. Ho,et al. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. , 1998, Virology.
[205] C. Broder,et al. N-Linked Glycosylation of CXCR4 Masks Coreceptor Function for CCR5-Dependent Human Immunodeficiency Virus Type 1 Isolates , 2000, Journal of Virology.
[206] G. Moyle,et al. The clades of HIV: their origins and clinical significance. , 2003, AIDS reviews.
[207] F. Cohen,et al. Taxonomy and conformational analysis of loops in proteins. , 1992, Journal of molecular biology.
[208] W. Vranken,et al. Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution. , 2001, European journal of biochemistry.
[209] B. Cullen,et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.
[210] C. M. Owens,et al. Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys. , 2004, AIDS research and human retroviruses.
[211] J. Sodroski,et al. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization , 1997, Journal of virology.
[212] G. Rose,et al. Loops in globular proteins: a novel category of secondary structure. , 1986, Science.
[213] William C. Olson,et al. Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes , 2001, Journal of Virology.
[214] R. Doms,et al. The entry of entry inhibitors: A fusion of science and medicine , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[215] J. Sodroski,et al. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions , 1993, Journal of virology.
[216] Feng Gao,et al. Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.
[217] J. Goudsmit,et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity , 1992, Journal of virology.
[218] A. Cann,et al. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism , 1993, Journal of virology.
[219] D. Burton,et al. Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities , 2003, Journal of Virology.
[220] P. Vernazza,et al. Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.
[221] B. Korber,et al. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. , 2004, Virology.
[222] A. Trkola,et al. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. , 1998, AIDS research and human retroviruses.
[223] Q. Sattentau,et al. HIV-1 attachment: another look. , 1999, Trends in microbiology.
[224] A. Trkola,et al. The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity* , 2001, The Journal of Biological Chemistry.
[225] Donald E. Mosier,et al. Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching , 2004, Journal of Virology.
[226] L. Morris,et al. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. , 2001, AIDS research and human retroviruses.
[227] D. Burton,et al. Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.
[228] A. Trkola,et al. The Differential Sensitivity of Human and Rhesus Macaque CCR5 to Small-Molecule Inhibitors of Human Immunodeficiency Virus Type 1 Entry Is Explained by a Single Amino Acid Difference and Suggests a Mechanism of Action for These Inhibitors , 2004, Journal of Virology.
[229] G. Quinnan,,et al. Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes , 1998, Journal of Virology.
[230] R. Means,et al. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus , 1997, Journal of virology.